Methods for making hiv vaccines and related compositions
AssigneeProteoNova, Inc.
InventorRichard B. Williams
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and kits for making a targeted therapeutic for prevent and treating HIV infection. In one of these methods, the method includes preparing a library of soluble peptides, and screening the library for proteins that bind to the region of CD4 that binds gp120. In this particular method, these proteins are used as the antigen to make the HIV vaccine.
Claims12
A method for making an antigenic composition that raises antibodies against HIV, the method comprising:
- preparing a population of soluble proteins;
- reacting a CD4 protein with a gp120 protein to generate a blocked CD4 protein comprising a gp120:CD4 complex;
- screening said population of soluble proteins for binding to said blocked CD4 protein;
- identifying a subpopulation of proteins from said population, wherein said subpopulation of proteins comprises proteins that do not bind to said blocked CD4 protein;
- and
- selecting at least one protein from said subpopulation;
- screening said at least one protein from said subpopulation for binding to an unblocked CD4 protein
- identifying at least one protein that binds to said unblocked CD4 protein,
- wherein said at least one protein that binds to said unblocked CD4 protein is used as an antigen for generating said antigenic composition.
(canceled)
A method for making a therapeutic for preventing or treating HIV, the method comprising:
- screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs having substantial affinity for CD4, wherein said mRNA-protein pairs do not bind a gp120:CD4 complex;
- isolating one or more proteins from the identified mRNA-protein pairs;
- and
- conjugating the isolated protein(s) to an adjuvant.
A method for making an antigenic composition that raises antibodies against HIV, the method comprising:
- preparing a population of soluble proteins;
- screening said population of soluble proteins for binding to an unblocked CD4 protein;
- identifying a subpopulation of proteins from said population, wherein said subpopulation of proteins comprises proteins that bind to said unblocked CD4 protein;
- reacting a CD4 protein with a gp120 protein to generate a blocked CD4 protein comprising a gp120:CD4 complex;
- screening said subpopulation of proteins that bind to said unblocked CD4 protein for binding to said blocked CD4 protein;
- identifying a second subpopulation of proteins from said subpopulation, wherein said second subpopulation of proteins comprises proteins that do not bind to said blocked CD4 protein;
- and
- selecting at least one protein from said second subpopulation;
- screening said at least one protein from said second subpopulation for binding to a second unblocked CD4 protein identifying at least one protein from said second subpopulation that binds to said second unblocked CD4 protein,
- wherein said at least one protein that binds to said second unblocked CD4 is used as an antigen for generating said antigenic composition.
Dependencies are inferred from the claim text.